Picard Medical, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - PMI [Accessibility Statement] Skip NavigationNEW YORK, Feb. 19, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Picard Medical, Inc. (NYSE: PMI).Shareholders who purchased shares of PMI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to ...

Group 1 - Moleculin Biotech, Inc. has entered into agreements for the immediate exercise of existing warrants to purchase up to 2,122,652 shares of common stock at an exercise price of $3.90 per share, expected to generate approximately $8.3 million in gross proceeds [1][4] - Roth Capital Partners is acting as the financial advisor for this transaction [2] - The company will issue new unregistered warrants for up to 6,367,956 shares, exercisable at the lesser of $3.90 or the lowest volume weighted average price during the next five trading days, subject to shareholder approval [3] Group 2 - The transaction is expected to close on or about February 20, 2026, pending customary closing conditions, with net proceeds intended for working capital and general corporate purposes [4] - The new warrants were offered in a private placement and have not been registered under the Securities Act of 1933, with the company agreeing to file a registration statement for the resale of shares [5] Group 3 - Moleculin Biotech is a Phase 3 clinical stage pharmaceutical company focused on developing therapeutic candidates for hard-to-treat tumors and viruses, with its lead program Annamycin targeting relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases [7][8] - The company has initiated the MIRACLE Trial, a pivotal Phase 3 trial evaluating Annamycin in combination with cytarabine for the treatment of relapsed or refractory acute myeloid leukemia, following a successful Phase 1B/2 study [8] - Additionally, the company is developing WP1066, an immune/transcription modulator targeting various cancers, and has a portfolio of antimetabolites including WP1122 for potential treatment of pathogenic viruses [9]

Performance in the Diversified segment improved primarily due to better net pricing realized during the fourth quarter.The acquisition of Shibo in China and DURECT's larsucosterol platform represent a strategic shift toward proactive business development to enhance long-term growth.Management attributed the 10% full-year adjusted EBITDA growth to portfolio optimization and increased operating leverage without the benefit of major acquisitions.International segment growth was supported by leading market posi ...

Core Viewpoint - AtaiBeckley NV has appointed Michael Faerm as chief financial officer, effective March 9, 2026, to enhance its financial strategy as it advances its mental health treatment pipeline [1]. Group 1: Appointment Details - Michael Faerm brings over 25 years of experience in life sciences, equity research, and investment banking [1]. - Faerm's previous roles include CFO at Viracta Therapeutics and interim CFO at Harpoon Therapeutics, which was acquired by Merck [2]. - He has also held positions at Innoviva, Forest Laboratories, and Regeneron Pharmaceuticals, focusing on business development and strategic finance [2]. Group 2: Financial Strategy and Leadership Transition - Faerm will oversee the company's financial strategy, capital markets activities, and overall financial operations [1]. - Current CFO Anne Johnson will transition to chief accounting officer, continuing to lead accounting and financial operations while supporting Faerm [3]. - The CEO of AtaiBeckley, Srinivas Rao, emphasized the importance of Faerm's strategic finance background as the company advances its lead candidate BPL-003 toward Phase 3 [4]. Group 3: Future Outlook - Faerm expressed enthusiasm about joining AtaiBeckley at a pivotal time, with BPL-003 advancing and a strong clinical-stage pipeline [5]. - He looks forward to collaborating with Johnson and the leadership team to support the company's late-stage development [6].

Core Insights - Goldman Sachs Conviction List features top stock picks for institutional and high-net-worth clients, highlighting companies with strong growth and income potential [1][2] - Five dividend-paying companies have been on the Conviction List for extended periods, all rated as Buy by Goldman Sachs [1] Company Summaries - **Bank of America (NYSE: BAC)**: - Dividend yield of 2.06% - Target price set at $67 - On the Conviction List for 362 days - Operates in Global Markets, Global Banking, Global Wealth & Investment Management, and Consumer Banking segments [1][2] - **Johnson & Johnson (NYSE: JNJ)**: - Dividend yield of 2.10% - Target price set at $250 - On the Conviction List for 275 days - Focuses on pharmaceuticals, biotechnology, and medical devices across Innovative Medicine and MedTech segments [1][2] - **Huntington Ingalls Industries (NYSE: HII)**: - Dividend yield of 1.33% - Target price set at $425 - On the Conviction List for 214 days - Engages in designing and constructing military ships and offers various naval nuclear support services [1][2] - **Duke Energy (NYSE: DUK)**: - Dividend yield of 3.37% - Target price set at $141 - On the Conviction List for 214 days - Operates in Electric Utilities and Infrastructure and Gas Utilities and Infrastructure segments [1][2] - **Kontoor Brands (NYSE: KTB)**: - Dividend yield of 3.09% - Target price set at $84 - On the Conviction List for 214 days - A global lifestyle apparel company with brands like Wrangler and Lee [1][2]

Group 1 - Vanda Pharmaceuticals Inc. reported a disappointing 4Q25 with a GAAP EPS of -$2.39, missing consensus by approximately $1.07 [1] - The company's revenue for the quarter was $57.22 million, which fell short of expectations by about $2.05 million [1] Group 2 - The article emphasizes the importance of evaluating the science behind drug candidates, the competitive landscape, clinical trial design, and potential market opportunities in the biotech sector [1] - It highlights the need for careful scrutiny in biotech investments, where breakthrough science can lead to significant returns but also carries inherent risks [1]

Group 1 - The son experienced a significant impact on his credit rating due to mingling finances with his girlfriend, which led to difficulties in applying for loans and apartments [2][3] - The girlfriend's spending habits included over $1,000 a month on weight-loss drugs, which contributed to financial strain [3][8] - The mother reflects on her own financial practices, emphasizing the importance of maintaining separate finances to avoid similar pitfalls [4] Group 2 - The son is ultimately responsible for his credit rating, indicating a need for personal accountability in financial decisions [5][7] - The situation highlights the importance of setting boundaries in personal and financial relationships to prevent future issues [6][7] - Weight-loss drugs, while costly, can be essential for health and may be justified despite their high price without insurance [8]

4Q25 Financial Results Feb. 19, 2026 NASDAQ: MDGL © 2026 Madrigal Pharmaceuticals, Inc. All rights reserved. Forward-looking Statements This presentation includes "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, that are based on Madrigal's beliefs and assumptions and on information currently available to it but are subject to factors beyond its control. Forward-looking statements reflect management's current knowledge, assumpt ...

Company Overview - Zealand Pharma A/S is a biotechnology company focused on advancing medicines for obesity and metabolic health, leveraging over 25 years of peptide R&D expertise and a proprietary data platform utilizing advanced data-driven and AI/ML approaches [2][3] - The company has more than ten drug candidates that have entered clinical development, with two products already on the market and three candidates in late-stage development [3] Annual General Meeting (AGM) Details - The Annual General Meeting for Zealand Pharma will take place on Thursday, March 26, 2026, at 03:00 PM CET / 9:00 AM ET, and will be conducted as a hybrid meeting allowing both electronic and in-person participation [1][2] - The meeting will be hosted electronically via a virtual meeting portal by Computershare A/S, with a physical location at the company's registered office in Søborg, Denmark [2]

ESTERO, FL / ACCESS Newswire / February 19, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company") today announced that its wholly owned subsidiary Buzz Bomb Caffeine Company - marketer of a proprietary caffeine supplement - has named ChicExecs as its public relations agency of record. The appointment comes as BUZZ BOMBâ"¢ gears up for a transformative year focused on aggressive brand expansion, product innovation, and a refreshed market presence. ...